Stockreport

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics, Inc.  (GLYC) 
Last glycomimetics, inc. earnings: 5/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.glycomimetics.com/investor-relations
PDF Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory [Read more]